选择性1型大麻素受体阻滞剂利莫那班

Rimonabant-a selective CB1 endocannabinoid receptor antagonist

利莫那班是选择性大麻素受体1(CBR1)阻滞剂,在对肥胖、戒烟以及代谢综合征治疗中具有良好作用,是惟一用于临床控制食欲和降低体重的内源性大麻素受体阻滞剂。现对其药理作用以及临床评价做一综述。

Rimonabant （ Aco have demonstrated beneficial effects mplia） is a selective cannabinoid receptor antagonist. Recent data of rimonabant in obesity, smoking cessation, and metabolic syndrome. It is the only endocannabinoid receptor antagonist in clinical development and thus offers a unique therapeutic approach to appetite control and weight reduction. The drug also has the potential for the treatment of smoking cessation because the endocannabinoid system is involved in the body＇s response to tobacco dependence. The pharmacological effect and pharmacotherapeutics of rimonabant are summarized in this paper.